Circassia Group Plc Settlement Agreement reached with Beyond Air (8038Z)

TIDMCIR

RNS Number : 8038Z

Circassia Group Plc

26 May 2021

CIRCASSIA GROUP PLC

Settlement Agreement reached with Beyond Air

Oxford, UK - 26 May 2021: Circassia Group plc ("Circassia" or "the Company"; AIM: CIR), a medical device company focused on respiratory diagnostics and monitoring, today announces that it has signed an agreement to settle its contractual dispute with Beyond Air Inc. with regard to the licensing to Circassia by Beyond Air in January 2019 of its LungFit (R) product (the "Settlement").

Under the terms of the original licence agreement, Circassia issued $10.5 million of Circassia shares to Beyond Air during the first half of 2019. Under the terms of the Settlement, Circassia will surrender its rights to the LungFit (R) product in exchange for payments by Beyond Air for up to a maximum of $16.5 million, payable in cash as follows:

   --      $2.5 million within 60 days of the approval of LungFit (R) by the FDA ("FDA approval") 
   --      $3.5 million within 60 days of the first anniversary of FDA approval 
   --      $4.5 million within 60 days of the second anniversary of FDA approval 

Circassia will also be entitled to a further royalty of 5% of net sales of LungFit (R), commencing on the second anniversary of FDA approval and capped at a maximum of $6 million.

Ian Johnson, Circassia's Executive Chairman, said: "We are pleased to have been able to resolve this dispute without recourse to formal arbitration, with its associated long timescales and significant legal expense."

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR") and is disclosed in accordance with the Company's obligations under UK MAR. This announcement is being made on behalf of the Company by the directors named below.

Contacts

Circassia

Ian Johnson, Executive Chairman Tel: [phone]

Michael Roller, Chief Financial Officer

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell/ Jen Boorer/ Hannah Woodley Tel: [phone]

About Circassia

Circassia is a medical device company focused on respiratory diagnostics and monitoring. Our market-leading NIOX(R) products are used in clinical settings by physicians around the world to help improve asthma diagnosis and management and by leading research organisations conducting clinical studies on behalf of pharmaceutical companies. Customers are able to buy products and receive customer service via dedicated teams in the United States, UK, Sweden, Germany and China, on-line in some regions and our network of global partners . For more information please visit www.circassia.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRFFFSIETIEFIL

(END) Dow Jones Newswires

May 26, 2021 02:00 ET (06:00 GMT)